Improved survival of AML patients by addition of cladribine to standard induction chemotherapy

• Published in: Annals of hematology Vol. 99; no. 3; pp. 519 - 525
• Main Authors: Anžej Doma, Saša, Škerget, Matevž, Pajič, Tadej, Sever, Matjaž
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-03-2020; Springer Nature B.V
• Subjects: Adult; Chemotherapy; Cladribine - administration & dosage; Disease-Free Survival; Female; Hematology; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - mortality; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Article; Remission (Medicine); Retrospective Studies; Survival Rate; AML; Remission; Induction chemotherapy; Survival; DA3+7; Cladribine
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-020-03923-9

One hundred and eight consecutive acute myeloid leukemia (AML) patients aged 60 or less treated with two different induction regimens were retrospectively analyzed. Induction regimen for the first 50 consecutive patients was DA3+7, and the following 58 patients received cladribine 5 mg/m
2
on days 1 through 5 in addition to DA3+7 (DAC). There were no significant differences in the median age and the proportion of patients with unfavorable characteristics between the two groups. Remission after induction chemotherapy was achieved in 30/50 (60%) patients in DA3+7 and in 46/58 (79%) in DAC group (
p
 = 0.028). The median survival in the DA3+7 group was 18 months, while in the DAC group it was not reached (
p
 = 0.034). We confirmed results from other research groups by demonstrating improved remission induction rate and overall survival of AML patients aged 60 years or less treated with DAC induction compared with standard DA3+7 induction chemotherapy.